RECRUITINGOBSERVATIONAL
Identification of New Biological Markers for the Progression of Mycobacterium Abscessus-induced Lung Disease in Cystic Fibrosis
About This Trial
In this project the investigators aim to identify new biological markers by characterizing the response/inflammation associated with the development and progression of M. abscessus lung disease in patients suffering from cystic fibrosis with the aim of increasing current knowledge available on the development and progression of lung disease.
Who May Be Eligible (Plain English)
Who May Qualify:
- Patients with a certain diagnosis of cystic fibrosis and visited during normal clinical practice, in accordance with the standard operating procedures in force at the Centres.
- Both sexes
- Age \>18 years
- Obtaining willing to sign a consent form for patients (based on the procedures established by the protocol).
Who Should NOT Join This Trial:
- Patients unable to understand the instructions and information provided and be able to adequately accept the study methods.
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* Patients with a certain diagnosis of cystic fibrosis and visited during normal clinical practice, in accordance with the standard operating procedures in force at the Centres.
* Both sexes
* Age \>18 years
* Obtaining informed consent for patients (based on the procedures established by the protocol).
Exclusion Criteria:
* Patients unable to understand the instructions and information provided and be able to adequately accept the study methods.
Treatments Being Tested
OTHER
Luminex; scRNAsec
Evaluation of specific cell populations associated with development of M. abscessus lung disease; evaluation of circulating factors related to immunoresponses
Locations (1)
Ospedale San Raffaele
Milan, MI, Italy